Sustaining Teva’s Generics Powerhouse in the Acceleration Phase

As Teva moves into a phase of acceleration, it continues to sustain its position as a generics’ powerhouse, providing affordable medicines globally, including biosimilars and Over the Counter (OTC) medicines. At a recent strategy day presentation to industry professionals, Richard Daniell, Executive VP European Commercial, outlined the forthcoming opportunities. 

Executive perspective

What are the 3 key elements essential to succeed in the generics market?

• A strong portfolio, valued by customers, alongside a broad pipeline of launches
• An excellent commercial platform with deep customer relationships
• An efficient and customer-service focused supply network

CEO perspective

How Teva is delivering in generics

Strong portfolio

Teva is one of the global leaders in generic and biosimilar medicines, driven by cutting-edge R&D and rigorous science. From everyday OTC treatments to complex generics and cutting edge biosimilars, we are redefining what’s possible with innovation, precision, and scale, increasing cost-effective options for patients and contributing to a more sustainable healthcare system.

Portfolio: Generics and new launches

“We have enjoyed considerable success in our generic business over the past two years as a key pillar of our pivot to growth strategy. We enjoy commercial leadership across all geographies and have a very thoughtful pipeline selection with high value and strong execution,” says Richard Daniells. 

Looking ahead, the opportunities are substantial as $175 billion of small molecule patents will expire in the US and Europe over the next six years – a 50% increase on the previous six years. Teva has strong coverage in that space - 60% in the US and 80% in Europe - supporting all market types from branded generics to International Non-proprietary Names (INN). 

Read more about our generics business

Portfolio: Complex generics 

Teva is one of the largest producers of complex generic medicines in the world.

“In the near term, we are launching 15 high value complex generics, including a large number in the US market,” says Richard Daniell. “In total, we have more than 300 dossiers under review globally - a strong world-leading pipeline that will give us solid growth through 2027 and beyond.” 

Read about our work in complex generics

Portfolio: Biosimilars 

With 13 assets in our biosimilar medicines pipeline, 6 products are expected to launch by 2027. 

“Forthcoming launches will address significant patent expirations in the future, amounting to $20 billion of innovative value,” says Richard Daniell. “This is a meaningful increased contribution to our generic powerhouse given our biosimilar base, and there is more to come as we bring through our early-stage pipeline. We're already covering $55 billion in innovative value here and we're selecting further assets right now to continue to rapidly build and diversify one of the best portfolios in the industry. In particular, we look forward to bringing more assets to Europe, leveraging our generic market leading position to grow our biosimilar business from this expanded and accelerated portfolio. We plan to double our biosimilar revenues over the next couple of years.” 

Find out more about our biosimilars business and go behind the scenes in our lab to see it in action.

Portfolio: Consumer healthcare/OTC

Teva has a billion dollar OTC business, which is mostly pharmacy driven. A key revenue contributor, it has a large synergy with our generics business. 

“OTC treatments and biosimilars represent about 25% of our business,” says Richard Daniell. “That's up from 16%, further adding to stability and robustness in the future.” 

Read more about our consumer healthcare products 

Commercial capabilities 

The evidence shows our launches are successful, as we’ve grown our generics business by 5% across all regions since 2024. A leader worldwide, we have strong pharmacy, hospital, wholesaler and payer relationships, and more than 55 markets across the globe. This provides benefits, scale and synergies across all our product categories - generics, biosimilars and OTC medicines. 

Supply network

Our supply network represents a considerable opportunity, and a fully-fledged transformation is currently underway to structure a leaner, more effective operation. Simplifying our network will free up capital, improve management and supply chains and make us more cost effective. Along with significant procurement, consolidation and scale benefits, this will lead to margin expansion and increased competitiveness. 

“Looking ahead to 2027, we will have a much more robust business with an increased contribution from biosimilars driven by an increased and accelerated portfolio, and from OTC, driven by our powerful medicine brands in a strong market,” explains Richard Daniell. “We will have less geographical reliance on the US, as it comes down to just 25% of our overall generic powerhouse business.” 

What comes next?

With a strong pipeline portfolio, market excellence and a great supply network, Teva’s generic portfolio will provide a solid base for accelerated growth from our innovative assets. Multiple growth drivers will provide stable revenues and gross margins, and competitiveness will increase as our operations network is transformed, underpinning our Pivot to Growth strategy acceleration. 

NPS-ALL-NP-01710 February 2026